Related Experiment Video
Updated: Feb 14, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF):
Habib Rehman Khan1,2,3, Ines Kralj-Hans1, Shouvik Haldar1,3
1Royal Brompton and Harefield NHS Trust, London, UK.
Insights
This trial compares catheter ablation and thoracoscopic surgical ablation for persistent atrial fibrillation. Results will guide treatment choices for this common arrhythmia.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Cardiac Surgery
Background:
- Atrial fibrillation is a prevalent arrhythmia increasing risks of heart failure, stroke, and mortality.
- Current treatments focus on rate/rhythm control and stroke risk reduction.
- Minimally invasive ablation techniques, including catheter and surgical approaches, offer alternative strategies.
Purpose of the Study:
- To compare the effectiveness and safety of percutaneous catheter ablation versus thoracoscopic surgical ablation for long-standing persistent atrial fibrillation.
- To evaluate the impact of these interventions on patients' quality of life.
Main Methods:
- A prospective, multi-centre, randomized controlled trial (CASA-AF) involving 120 adults with symptomatic, long-standing, persistent atrial fibrillation.
- Patients were randomized 1:1 to catheter ablation or thoracoscopic ablation.
- Continuous rhythm monitoring using implantable loop recorders for 12 months, with primary endpoint of freedom from atrial fibrillation/atrial tachycardia.
Main Results:
- The study is designed to provide comparative data on efficacy and safety.
- Continuous monitoring via implantable loop recorders will offer detailed rhythm assessment.
- Quality of life assessments will be conducted throughout the 12-month follow-up period.
Conclusions:
- The CASA-AF trial will offer high-quality evidence on the comparative efficacy, safety, and cost-effectiveness of two key ablation strategies.
- Findings will inform clinical decision-making for patients with long-standing persistent atrial fibrillation.
- The study will also elucidate the effects on patient-reported quality of life.
Background:
Atrial fibrillation is the commonest arrhythmia which raises the risk of heart failure, thromboembolic stroke, morbidity and death. Pharmacological treatments of this condition are focused on heart rate control, rhythm control and reduction in risk of stroke. Selective ablation of cardiac tissues resulting in isolation of areas causing atrial fibrillation is another treatment strategy which can be delivered by two minimally invasive interventions: percutaneous catheter ablation and thoracoscopic surgical ablation. The main purpose of this trial is to compare the effectiveness and safety of these two interventions.
Methods/Design:
Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF) is a prospective, multi-centre, randomised controlled trial within three NHS tertiary cardiovascular centres specialising in treatment of atrial fibrillation. Eligible adults (n = 120) with symptomatic, long-standing, persistent atrial fibrillation will be randomly allocated to either catheter ablation or thoracoscopic ablation in a 1:1 ratio. Pre-determined lesion sets will be delivered in each treatment arm with confirmation of appropriate conduction block. All patients will have an implantable loop recorder (ILR) inserted subcutaneously immediately following ablation to enable continuous heart rhythm monitoring for at least 12 months. The devices will be programmed to detect episodes of atrial fibrillation and atrial tachycardia ≥ 30 s in duration. The patients will be followed for 12 months, completing appropriate clinical assessments and questionnaires every 3 months. The ILR data will be wirelessly transmitted daily and evaluated every month for the duration of the follow-up. The primary endpoint in the study is freedom from atrial fibrillation and atrial tachycardia at the end of the follow-up period.
Discussion:
The CASA-AF Trial is a National Institute for Health Research-funded study that will provide first-class evidence on the comparative efficacy, safety and cost-effectiveness of thoracoscopic surgical ablation and conventional percutaneous catheter ablation for long-standing persistent atrial fibrillation. In addition, the results of the trial will provide information on the effects on patients' quality of life.
Trial Registration:
ISRCTN Registry, ISRCTN18250790 . Registered on 24 April 2015.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Standing Waves
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Trial and Error and Algorithm

